HUT64601A - Method for producing purified immunoglobulin - Google Patents

Method for producing purified immunoglobulin Download PDF

Info

Publication number
HUT64601A
HUT64601A HU9202000A HU200092A HUT64601A HU T64601 A HUT64601 A HU T64601A HU 9202000 A HU9202000 A HU 9202000A HU 200092 A HU200092 A HU 200092A HU T64601 A HUT64601 A HU T64601A
Authority
HU
Hungary
Prior art keywords
antibody
column
formulation
protein
campath
Prior art date
Application number
HU9202000A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9202000D0 (en
Inventor
Paul Ian Nicholas Ramage
Geoffrey Allen
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUT64601(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of HU9202000D0 publication Critical patent/HU9202000D0/hu
Publication of HUT64601A publication Critical patent/HUT64601A/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU9202000A 1990-10-17 1991-10-17 Method for producing purified immunoglobulin HUT64601A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909022547A GB9022547D0 (en) 1990-10-17 1990-10-17 Purified immunoglobulin

Publications (2)

Publication Number Publication Date
HU9202000D0 HU9202000D0 (en) 1992-10-28
HUT64601A true HUT64601A (en) 1994-01-28

Family

ID=10683866

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9202000A HUT64601A (en) 1990-10-17 1991-10-17 Method for producing purified immunoglobulin

Country Status (29)

Country Link
US (1) US5644036A (enExample)
EP (1) EP0504363B2 (enExample)
JP (1) JP2638680B2 (enExample)
KR (2) KR960015399B1 (enExample)
AT (2) ATA900791A (enExample)
AU (3) AU658926B2 (enExample)
BE (1) BE1004226A5 (enExample)
BR (1) BR1100358A (enExample)
CA (1) CA2069481C (enExample)
CH (2) CH681455A5 (enExample)
DE (1) DE69128774T3 (enExample)
DK (1) DK0504363T4 (enExample)
ES (2) ES2112865T5 (enExample)
FI (2) FI110003B (enExample)
FR (2) FR2668164A1 (enExample)
GB (2) GB9022547D0 (enExample)
GR (3) GR910100425A (enExample)
HU (1) HUT64601A (enExample)
IE (1) IE913560A1 (enExample)
IL (3) IL99761A0 (enExample)
IT (1) IT1250064B (enExample)
LU (1) LU88122A1 (enExample)
MX (1) MX9203794A (enExample)
MY (2) MY136210A (enExample)
NZ (2) NZ244114A (enExample)
PT (2) PT99248B (enExample)
TW (1) TW283710B (enExample)
WO (1) WO1992007084A1 (enExample)
ZA (2) ZA918259B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
EP0610447B1 (en) * 1991-10-15 1998-12-16 Btg International Limited CDw52 - SPECIFIC ANTIBODY FOR TREATMENT OF T-CELL MEDIATED INFLAMMATION OF THE JOINTS
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB9300501D0 (en) * 1993-01-09 1993-03-03 Wellcome Found Purification of immunoglobulin
NZ315357A (en) † 1995-08-01 1999-08-30 Pasteur Merieux Serums Vacc Method for industrially producing a japanese encephalitis vaccine, and resulting vaccine
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE69721548T2 (de) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
WO2002072615A1 (en) * 2001-03-09 2002-09-19 Chugai Seiyaku Kabushiki Kaisha Method of purifying protein
DK1714982T3 (da) * 2001-06-05 2009-05-04 Genetics Inst Llc Fremgangsmåde til rensning af stærkt anioniske proteiner
GB0220894D0 (en) * 2002-09-09 2002-10-16 Millipore Uk Ltd Method of separation
SI1561756T1 (sl) 2002-09-11 2016-02-29 Chugai Seiyaku Kabushiki Kaisha Postopek čiščenja proteinov
US7485710B2 (en) 2002-10-15 2009-02-03 Intercell Ag Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
JP2007515492A (ja) * 2003-12-22 2007-06-14 ジェンザイム コーポレイション 糖尿病の抗ｃｄ５２抗体治療法
KR101482791B1 (ko) * 2005-03-11 2015-01-21 와이어쓰 엘엘씨 약한 분배성 크로마토그래피법
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
PT2708559T (pt) 2008-04-11 2018-05-16 Chugai Pharmaceutical Co Ltd Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio
JP5834004B2 (ja) 2009-05-13 2015-12-16 ジェンザイム・コーポレーション ループス治療のための方法および組成物
KR20160005143A (ko) 2009-05-13 2016-01-13 젠자임 코포레이션 항-인간 ｃｄ52 면역글루불린
EP2519536A4 (en) * 2009-12-29 2013-06-05 Reddys Lab Ltd Dr PROTEIN PURIFICATION BY ION EXCHANGE
WO2011162210A1 (ja) 2010-06-21 2011-12-29 協和発酵キリン株式会社 アミノ酸を利用したタンパク質の精製方法
RU2467783C2 (ru) * 2010-07-30 2012-11-27 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения иммуноглобулина
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN106029682B (zh) 2013-12-27 2021-04-13 中外制药株式会社 等电点低的抗体的纯化方法
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
US10858391B2 (en) 2015-07-31 2020-12-08 Chugai Seiyaku Kabushiki Kaisha Method for purifying composition comprising antibodies with anionic polymer
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
MX392628B (es) 2016-07-25 2025-03-24 Cephalon Inc Amortiguador de lavado de cromatografia de afinidad.
KR102538749B1 (ko) 2016-08-05 2023-06-01 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
CN113646066B (zh) 2019-03-29 2024-05-31 旭化成医疗株式会社 蛋白质的纯化方法
EP3954725B1 (en) 2019-04-08 2024-03-06 Asahi Kasei Medical Co., Ltd. Polyamide medium for purifying protein-containing solution and method for producing polyamide medium
BR112021020204A2 (pt) 2019-04-10 2021-12-07 Chugai Pharmaceutical Co Ltd Método para purificar anticorpo com região fc modificada
WO2022260091A1 (ja) 2021-06-10 2022-12-15 三菱ケミカル株式会社 合成吸着剤、抗体の精製方法及び抗体の製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
WO1989007452A1 (en) * 1988-02-12 1989-08-24 Medical Research Council Improvements in or relating to antibodies

Also Published As

Publication number Publication date
EP0504363B1 (en) 1998-01-21
AU716402B2 (en) 2000-02-24
IL102726A (en) 2002-08-14
DE69128774D1 (de) 1998-02-26
GR920100471A (el) 1994-06-30
AU4521897A (en) 1998-02-12
AU2532192A (en) 1993-02-11
ITRM910788A0 (it) 1991-10-16
IL99761A0 (en) 1992-08-18
KR960015399B1 (ko) 1996-11-13
KR100193314B1 (ko) 1999-06-15
FI922824A0 (fi) 1992-06-17
MX9203794A (es) 1992-07-01
ATE162552T1 (de) 1998-02-15
PT100988A (pt) 1994-02-28
AU649078B2 (en) 1994-05-12
ATA900791A (de) 1996-06-15
DE69128774T2 (de) 1998-06-04
ZA926191B (en) 1993-04-16
LU88122A1 (fr) 1993-03-15
AU658926B2 (en) 1995-05-04
IT1250064B (it) 1995-03-30
CH681305A5 (enExample) 1993-02-26
CA2069481C (en) 2003-07-29
PT99248A (pt) 1993-06-30
MY136210A (en) 2008-08-29
IL102726A0 (en) 1993-01-31
DE69128774T3 (de) 2007-08-16
ES2081742B1 (es) 1996-10-01
JP2638680B2 (ja) 1997-08-06
TW283710B (enExample) 1996-08-21
EP0504363B2 (en) 2007-02-07
BR1100358A (pt) 2000-03-28
PT99248B (pt) 1999-04-30
ES2112865T3 (es) 1998-04-16
ES2081742A1 (es) 1996-03-01
HU9202000D0 (en) 1992-10-28
WO1992007084A1 (en) 1992-04-30
NZ240247A (en) 1994-03-25
JPH05504579A (ja) 1993-07-15
US5644036A (en) 1997-07-01
GR3026588T3 (en) 1998-07-31
FI110003B (fi) 2002-11-15
GB2253397A (en) 1992-09-09
ES2112865T5 (es) 2007-09-16
PT100988B (pt) 1999-08-31
DK0504363T3 (da) 1998-09-21
IE913560A1 (en) 1992-04-22
NZ244114A (en) 1995-06-27
FR2668164B1 (enExample) 1995-04-14
KR920703108A (ko) 1992-12-17
MY119030A (en) 2005-03-31
FR2677997A1 (fr) 1992-12-24
GR910100425A (el) 1992-09-25
DK0504363T4 (da) 2007-05-29
FI922380A0 (fi) 1992-05-25
FI922380L (fi) 1992-05-25
ZA918259B (en) 1993-04-16
GB9209529D0 (en) 1992-07-01
FI922824L (fi) 1992-06-17
BE1004226A5 (fr) 1992-10-13
FI110002B (fi) 2002-11-15
CH681455A5 (enExample) 1993-03-31
GB9022547D0 (en) 1990-11-28
FR2668164A1 (fr) 1992-04-24
CA2069481A1 (en) 1992-04-18
ITRM910788A1 (it) 1993-04-16
AU7024294A (en) 1995-01-05
EP0504363A1 (en) 1992-09-23
AU8729491A (en) 1992-05-20

Similar Documents

Publication Publication Date Title
HUT64601A (en) Method for producing purified immunoglobulin
IE84931B1 (en) Purified IgG Antibodies
CA2053585C (en) Antibody production in chinese hamster ovary cells
CA2330170C (en) Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
US5750106A (en) Human monoclonal antibodies to cytomegalovirus
KR102578087B1 (ko) 숙주세포 갈렉틴(galectins) 및 다른 오염물(contaminant)로부터 글리코실화 단백질을 정제하는 방법
CN116547298A (zh) 猫抗体恒定区中的突变
JP4249028B2 (ja) 蛋白質の活性化方法
AU649078C (en) Purified CDW52-specific antibodies
Hanashiro et al. Production of a monoclonal dinitrophenyl-specific rat IgE and establishment of an IgE capture ELISA for estimating the concentration of rat IgE antibodies to dinitrophenyl-Ascaris suum
EP2272872A1 (en) Monoclonal antibody specifically recognizing human interferon alpha subtype alpha-8 and mutant protein thereof
WO1994015950A1 (en) Purification of immunoglobulin
Kanoksilapatham Production of anti-leukemic monoclonal antibodies
NZ795260A (en) Manufacturing Optimization of GL-2045, a Multimerizing Stradomer

Legal Events

Date Code Title Description
DFC4 Cancellation of temporary protection due to refusal